In this trial, the dog was treated with
The dog in the study is a 4-year-old intact male border collie dog with a body weight of 22 kg, suffering from refractory idiopathic (drug-resistant) epilepsy. The dog was treated with three anti-epileptic drugs but was still suffering from seizures several times a month and was hospitalized approximately once a month in order to stop epileptic clusters (frequent seizure events, i.e., every couple of hours) by using intravenous medications. The dog was treated with several injections of
Epilepsy is a chronic brain disorder characterized by sudden and recurrent episodes of seizures. It is one of the most common neurological disorders worldwide, affecting people of all ages. Presently, around 50 million patients are living with epilepsy worldwide and about 2.4 million new cases are diagnosed annually. (
The Global Anti Epilepsy Drugs Market Size was estimated at
Professor Chezy Barenholz of
'Our innovation and IP bring effective results in the pre-clinical stage, and Innocan is determined to complete significant sets of lab experiments soon. We see positive results and are pushing forward,' said Iris Bincovich, CEO of Innocan.
Innocan's Unique Solution
By administering CBD encapsulated in liposomes (the LPT platform), Innocan seeks to achieve long-lasting and significant levels of CBD in the body. Innocan believes this will create a far more effective and continuous therapeutic effect.
Innocan carried out a series of experiments of its LPT platform on animals. These experiments have demonstrated initial positive results, validating the viability of Innocan's intention to make CBD available to humans and animals for extended periods upon a single dosage.
Innocan's unique delivery method allows for the controlled release of CBD into the bloodstream with improved pharmacokinetic (PK) performance. The research was conducted in collaboration with the
Innocan's relationship with
About Innocan
Innocan is a pharmaceutical technology company that focuses on the development of several drug delivery platforms containing CBD.
Contact:
Iris Bincovich
Tel: 1-516-210-4025
Email: info@innocanpharma.com
Caution regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
(C) 2022 Electronic News Publishing, source